Global Fibromyalgia Treatment Market Size By Drug Class (Antidepressants, Anticonvulsants, Analgesics, Muscle Relaxants), By Treatment (Medication, Therapy, Lifestyle Changes), By End-Users (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast
Report ID: 36116|No. of Pages: 202
Global Fibromyalgia Treatment Market Size By Drug Class (Antidepressants, Anticonvulsants, Analgesics, Muscle Relaxants), By Treatment (Medication, Therapy, Lifestyle Changes), By End-Users (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast
Fibromyalgia Treatment Market Size And Forecast
Fibromyalgia Treatment Market size was valued at USD 1811.76 Million in 2024 and is projected to reach USD 2508.28 Million by 2031, growing at a CAGR of 4.15% from 2024 to 2031.
- Fibromyalgia treatment refers to the range of medical therapies, medications, and other solutions designed to manage the symptoms of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties.
- This is primarily utilized by healthcare providers, including hospitals, clinics, and pharmacies, to treat patients suffering from fibromyalgia.
- Medications like pain relievers, antidepressants, and anti-seizure drugs, as well as physical therapy and counseling, are commonly used in fibromyalgia management.
- It is used to improve the quality of life for fibromyalgia patients by alleviating symptoms, reducing pain, and managing associated conditions such as sleep disturbances and depression.
- As the understanding of fibromyalgia improves, the market is expanding with new treatment options, catering to the growing number of patients seeking relief from this chronic, often debilitating condition.
- Fibromyalgia is a long-term disorder that causes pain throughout the body, fatigue, and difficulties with sleep, memory, and mood.
- Due to the chronic nature of the condition and the variety of symptoms associated with it, treatment is primarily focused on managing the symptoms rather than curing the disease.
Global Fibromyalgia Treatment Market Dynamics
The key market dynamics that are shaping the global fibromyalgia treatment market include:
Key Market Drivers
- Increasing Prevalence of Fibromyalgia: The rising number of people diagnosed with fibromyalgia globally is driving demand for effective treatment options.
- Growing Awareness of the Disorder: Enhanced public awareness and better diagnostic methods are leading to more individuals seeking treatment.
- Advancements in Drug Development: The National Institutes of Health (NIH) reported funding for fibromyalgia research increased from $13 million in 2019 to $18 million in 2023, a 38% increase. According to the FDA, there are currently over 25 clinical trials specifically focused on fibromyalgia treatments in various phases. Pharmaceutical companies are focusing on the development of new and more effective drugs for fibromyalgia, driving market growth.
- Improved Healthcare Infrastructure: Expanding healthcare facilities, especially in developing regions, is increasing access to fibromyalgia treatments.
- Rising Demand for Non-Pharmaceutical Therapies: The growing preference for alternative therapies like cognitive behavioral therapy (CBT) and physical rehabilitation is boosting market growth.
Key Market Challenges:
- Difficulty in Diagnosis: Fibromyalgia can be difficult to diagnose due to overlapping symptoms with other conditions, hindering timely treatment.
- Limited Awareness in Developing Regions: Lack of awareness and diagnostic tools in certain regions limits the market potential.
- Side Effects of Existing Medications: Many fibromyalgia drugs have significant side effects, affecting patient adherence and market growth.
- High Treatment Costs: The expense of medications and therapies can limit access, particularly in low-income areas.
- Lack of Curative Treatment: The absence of a permanent cure restricts the market to symptom management, limiting long-term effectiveness.
Key Market Trends:
- Development of Personalized Medicine: The increasing focus on personalized treatment approaches is gaining traction in the fibromyalgia market.
- Integration of Telemedicine: Telemedicine platforms are becoming more prevalent, allowing patients easier access to consultations and follow-ups.
- Non-Pharmaceutical Treatment Growth: More patients are opting for alternative therapies such as mindfulness, acupuncture, and exercise programs.
- Combination Therapies: There is a growing trend toward combining pharmaceutical and non-pharmaceutical treatments for more comprehensive care.
- Research in Biologics: New research is being conducted into biologics and novel therapies that target the root causes of fibromyalgia symptoms, promising more effective solutions in the future.
What's inside a VMR
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=36116
Global Fibromyalgia Treatment Market Regional Analysis
Here is a more detailed regional analysis of the fibromyalgia treatment market:
North America
- The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure.
- According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population.
- The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases.
- The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.
- The presence of key pharmaceutical companies focused on developing innovative therapies for fibromyalgia further strengthens the region’s market position.
- Growing research and development activities aimed at discovering new drugs and treatment modalities have fueled market expansion.
- Government initiatives and healthcare programs in the U.S. and Canada to promote awareness and provide access to treatment for chronic pain conditions have played a crucial role in market growth.
- The rising demand for personalized medicine and alternative therapies such as cognitive behavioral therapy (CBT), physiotherapy, and mindfulness practices is also influencing the market dynamics in North America.
- The high cost of treatment and the side effects associated with some medications remain key challenges in the region.
- Despite this, North America’s dominant healthcare infrastructure and ongoing advancements in fibromyalgia treatment continue to drive market growth.
Asia Pacific
- The Asia Pacific region is anticipated to witness the fastest growth in the Global Fibromyalgia Treatment Market, driven by increasing awareness of chronic pain conditions and improving healthcare infrastructure.
- Countries such as China, Japan, India, and South Korea are contributing to market expansion as healthcare access becomes more widespread and diagnosis rates for fibromyalgia improve.
- The region’s growing aging population is also a key factor, as fibromyalgia tends to affect older adults more frequently.
- Rising healthcare expenditure and the availability of affordable treatment options are facilitating the market’s growth in Asia Pacific.
- Governments in countries like India and China are initiating healthcare reforms aimed at increasing the accessibility of pain management therapies, which is positively impacting the fibromyalgia treatment market.
- Despite these advancements, challenges such as low awareness in rural areas and limited availability of specialized treatment centers pose obstacles to market growth.
- The increasing focus on research and development, along with the growing demand for non-invasive treatments and alternative therapies like acupuncture and herbal medicines, is expected to drive continued growth in the Asia Pacific fibromyalgia treatment market in the coming years.
Global Fibromyalgia Treatment Market: Segmentation Analysis
The Global Fibromyalgia Treatment Market is segmented based on Drug Class, Treatment, End-Users, and Geography.
Fibromyalgia Treatment Market, By Drug Class
- Antidepressants
- Anticonvulsants
- Analgesics
- Muscle Relaxants
Based on drug class, the Global Fibromyalgia Treatment Market is segmented into Antidepressants, Anticonvulsants, Analgesics, and Muscle Relaxants. The Antidepressant segment significantly dominates the Global Fibromyalgia Treatment Market owing to their effectiveness in reducing pain and improving mood in fibromyalgia patients.
Fibromyalgia Treatment Market, By Treatment
- Medication
- Therapy
- Lifestyle Changes
Based on treatment, the Global Fibromyalgia Treatment Market is segmented into Medication, Therapy, and Lifestyle Changes. The Medication segment significantly dominates the Global Fibromyalgia Treatment Market owing to its central role in symptom management, with drugs like antidepressants and pain relievers commonly prescribed.
Fibromyalgia Treatment Market, By End-Users
- Hospitals
- Clinics
- Retail Pharmacies
- Online Pharmacies
Based on end-users, the Global Fibromyalgia Treatment Market is segmented into Hospitals, Clinics, Retail Pharmacies, and Online Pharmacies. Hospitals significantly dominate the Global Fibromyalgia Treatment Market owing to the availability of specialized care and advanced treatment options for fibromyalgia patients.
Fibromyalgia Treatment Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
Based on Geography, the global fibromyalgia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population. The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases. The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.
Key Players
The “Global Fibromyalgia Treatment Market” study report provides valuable insight with an emphasis on the global market. The major players in the market are Fizer, Innovative Med Concepts, Novartis AG, Eli Lilly & Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., AbbVie, FSD Pharma, Merck & Co., Teva Pharmaceutical Industries Ltd., Lupin Limited, Viatris Inc., Tonix Pharmaceuticals Holding Corp., and Aptinyx Inc.
This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Global Fibromyalgia Treatment Market Key Developments
- In August 2022, Aptinyx Inc. announced the results from a Phase 2b clinical study that evaluated the effects of NYX-2925 in patients with fibromyalgia. The study revealed that NYX-2925 did not achieve statistically significant separation from placebo on the primary endpoint, which measured the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
- In October 2020, Eli Lily announced a collaboration with Daiichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody potentially used to treat migraines. Under this agreement, Daiichi Sankyo was responsible for the sales and distribution of Galcanezumab, while Eli Lily Japan retained the marketing license, pending marketing approval.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| STUDY PERIOD | 2021-2031 |
| BASE YEAR | 2024 |
| FORECAST PERIOD | 2024-2031 |
| HISTORICAL PERIOD | 2021-2023 |
| UNIT | Value (USD Million) |
| KEY COMPANIES PROFILED | Fizer, Innovative Med Concepts, Novartis AG, Eli Lilly & Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., AbbVie, FSD Pharma, Merck & Co., Teva Pharmaceutical Industries Ltd., Lupin Limited, Viatris Inc., Tonix Pharmaceuticals Holding Corp., and Aptinyx Inc. |
| SEGMENTS COVERED | By Drug Class, By Treatment, By End-Users, and By Geography. |
| CUSTOMIZATION SCOPE | Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Research Methodology of Verified Market Research
To know more about the Research Methodology and other aspects of the research study, kindly Get in touch with our sales team.
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.
Frequently Asked Questions
1 INTRODUCTION
1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP-DOWN APPROACH
2.10 RESEARCH FLOW
2.11 DATA SOURCES
3 EXECUTIVE SUMMARY
3.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OVERVIEW
3.2 GLOBAL FIBROMYALGIA TREATMENT ECOLOGY MAPPING
3.3 GLOBAL FIBROMYALGIA TREATMENT ABSOLUTE MARKET OPPORTUNITY
3.4 GLOBAL FIBROMYALGIA TREATMENT MARKET ATTRACTIVENESS, BY REGION
3.5 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.6 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
3.7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
3.8 FUTURE MARKET OPPORTUNITIES
3.9 GLOBAL MARKET SPLIT
4 MARKET OUTLOOK
4.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
4.2 MARKET EVOLUTION
4.3 MARKET DRIVERS
4.3.1 APPROVAL AND LAUNCH OF NOVEL FIBROMYALGIA TREATMENT DRUGS
4.3.2 STRONG PRODUCT PIPELINE AND INCREASING OCCURRENCE OF FIBROMYALGIA
4.4 RESTRAINTS
4.4.1 SIDE EFFECTS OF THE DRUGS USED FOR THE TREATMENT OF FIBROMYALGIA
4.4.2 HIGHER ADOPTION OF OFF-LABEL AND GENERIC DRUGS
4.5 OPPORTUNITIES
4.5.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NEW THERAPIES FOR THE TREATMENT OF FIBROMYALGIA
4.6 IMPACT OF COVID-19 ON GLOBAL FIBROMYALGIA TREATMENT MARKET
4.7 MACROECONOMIC ANALYSIS
4.8 PORTER’S FIVE FORCES ANALYSIS
4.8.1 THREAT OF NEW ENTRANTS
4.8.2 THREAT OF SUBSTITUTES
4.8.3 BARGAINING POWER OF SUPPLIERS
4.8.4 BARGAINING POWER OF BUYERS
4.8.5 INTENSITY OF COMPETITIVE RIVALRY
4.9 PRICING ANALYSIS
5 MARKET, BY DRUG CLASS
5.1 OVERVIEW
5.2 ANTIDEPRESSANTS
5.3 ANTICONVULSANTS
5.4 ANALGESICS
5.5 MUSCLE RELAXANTS
6 MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 MEDICATION
6.3 THERAPY
6.4 LIFESTYLE CHANGES
7 MARKET, BY END-USERS
7.1 OVERVIEW
7.2 HOSPITALS
7.2 CLINICS
8 MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 GERMANY
8.3.3 U.K.
8.3.4 FRANCE
8.3.5 ITALY
8.3.6 SPAIN
8.3.7 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 INDIA
8.4.4 JAPAN
8.4.5 REST OF ASIA PACIFIC
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA MARKET SNAPSHOT
8.5.2 BRAZIL
8.5.3 ARGENTINA
8.5.4 REST OF LATIN AMERICA
8.6 MIDDLE EAST AND AFRICA
8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
8.6.2 UAE
8.6.3 SAUDI ARABIA
8.6.4 SOUTH AFRICA
8.6.5 REST OF MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING ANALYSIS,
9.3 COMPANY REGIONAL FOOTPRINT
9.4 COMPANY INDUSTRY FOOTPRINT
9.5 ACE MATRIX
9.5.1 ACTIVE
9.5.2 CUTTING EDGE
9.5.3 EMERGING
9.5.4 INNOVATORS
10 COMPANY PROFILES
10.1 PFIZER
10.1.1 COMPANY OVERVIEW
10.1.2 COMPANY INSIGHTS
10.1.3 SEGMENT BREAKDOWN
10.1.4 PRODUCT BENCHMARKING
10.1.5 KEY DEVELOPMENTS
10.1.6 WINNING IMPERATIVES
10.1.7 CURRENT FOCUS & STRATEGIES
10.1.8 THREAT FROM COMPETITION
10.1.9 SWOT ANALYSIS
10.2 INNOVATIVE MED CONCEPTS
10.2.1 COMPANY OVERVIEW
10.2.2 COMPANY INSIGHTS
10.2.3 SEGMENT BREAKDOWN
10.2.4 PRODUCT BENCHMARKING
10.2.5 KEY DEVELOPMENTS
10.2.6 WINNING IMPERATIVES
10.2.7 CURRENT FOCUS & STRATEGIES
10.2.8 THREAT FROM COMPETITION
10.2.9 SWOT ANALYSIS
10.3 NOVARTIS AG
10.3.1 COMPANY OVERVIEW
10.3.2 COMPANY INSIGHTS
10.3.3 SEGMENT BREAKDOWN
10.3.4 PRODUCT BENCHMARKING
10.3.5 KEY DEVELOPMENTS
10.3.6 WINNING IMPERATIVES
10.3.7 CURRENT FOCUS & STRATEGIES
10.3.8 THREAT FROM COMPETITION
10.3.9 SWOT ANALYSIS
10.4 ELI LILLY & COMPANY
10.4.1 COMPANY OVERVIEW
10.4.2 COMPANY INSIGHTS
10.4.3 SEGMENT BREAKDOWN
10.4.4 PRODUCT BENCHMARKING
10.4.5 KEY DEVELOPMENTS
10.4.6 WINNING IMPERATIVES
10.4.7 CURRENT FOCUS & STRATEGIES
10.4.8 THREAT FROM COMPETITION
10.4.9 SWOT ANALYSIS
10.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
10.5.1 COMPANY OVERVIEW
10.5.2 COMPANY INSIGHTS
10.5.3 SEGMENT BREAKDOWN
10.5.4 PRODUCT BENCHMARKING
10.5.5 KEY DEVELOPMENTS
10.5.6 WINNING IMPERATIVES
10.5.7 CURRENT FOCUS & STRATEGIES
10.5.8 THREAT FROM COMPETITION
10.5.9 SWOT ANALYSIS
10.6 INTEC PHARMA LTD.
10.6.1 COMPANY OVERVIEW
10.6.2 COMPANY INSIGHTS
10.6.3 SEGMENT BREAKDOWN
10.6.4 PRODUCT BENCHMARKING
10.6.5 KEY DEVELOPMENTS
10.6.6 WINNING IMPERATIVES
10.6.7 CURRENT FOCUS & STRATEGIES
10.6.8 THREAT FROM COMPETITION
10.6.9 SWOT ANALYSIS
10.7 ABBVIE
10.7.1 COMPANY OVERVIEW
10.7.2 COMPANY INSIGHTS
10.7.3 SEGMENT BREAKDOWN
10.7.4 PRODUCT BENCHMARKING
10.7.5 KEY DEVELOPMENTS
10.7.6 WINNING IMPERATIVES
10.7.7 CURRENT FOCUS & STRATEGIES
10.7.8 THREAT FROM COMPETITION
10.7.9 SWOT ANALYSIS
10.8 FSD PHARMA
10.8.1 COMPANY OVERVIEW
10.8.2 COMPANY INSIGHTS
10.8.3 SEGMENT BREAKDOWN
10.8.4 PRODUCT BENCHMARKING
10.8.5 KEY DEVELOPMENTS
10.8.6 WINNING IMPERATIVES
10.8.7 CURRENT FOCUS & STRATEGIES
10.8.8 THREAT FROM COMPETITION
10.8.9 SWOT ANALYSIS
10.9 MERCK & CO.
10.9.1 COMPANY OVERVIEW
10.9.2 COMPANY INSIGHTS
10.9.3 SEGMENT BREAKDOWN
10.9.4 PRODUCT BENCHMARKING
10.9.5 KEY DEVELOPMENTS
10.9.6 WINNING IMPERATIVES
10.9.7 CURRENT FOCUS & STRATEGIES
10.9.8 THREAT FROM COMPETITION
10.9.9 SWOT ANALYSIS
10.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.10.1 COMPANY OVERVIEW
10.10.2 COMPANY INSIGHTS
10.10.3 SEGMENT BREAKDOWN
10.10.4 PRODUCT BENCHMARKING
10.10.5 KEY DEVELOPMENTS
10.10.6 WINNING IMPERATIVES
10.10.7 CURRENT FOCUS & STRATEGIES
10.10.8 THREAT FROM COMPETITION
10.10.9 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
TABLE 2 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 3 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
TABLE 5 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 6 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 7 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 8 U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 9 U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 10 CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 11 CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 12 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 13 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 14 EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 15 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 16 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 17 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 18 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 19 U.K. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 20 U.K. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 21 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 22 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 23 ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 24 ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 25 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 26 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 27 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 28 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 32 CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 33 CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 34 INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 35 INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 36 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 37 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS 2022-2030 (USD MILLION)
TABLE 38 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 39 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 40 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 41 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 42 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 43 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 44 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 45 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 46 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 47 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 48 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 52 UAE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 53 UAE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 54 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 55 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 56 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 57 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 58 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
TABLE 59 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
TABLE 60 COMPANY MARKET RANKING ANALYSIS
TABLE 61 COMPANY REGIONAL FOOTPRINT
TABLE 62 COMPANY INDUSTRY FOOTPRINT
TABLE 63 PFIZER INC.: PRODUCT BENCHMARKING
TABLE 64 PFIZER INC.: WINNING IMPERATIVES
TABLE 65 NOVARTIS AG: PRODUCT BENCHMARKING
TABLE 66 NOVARTIS AG: WINNING IMPERATIVES
TABLE 67 ABBVIE: PRODUCT BENCHMARKING
TABLE 68 ABBVIE: KEY DEVELOPMENTS
TABLE 69 ABBVIE: WINNING IMPERATIVES
TABLE 70 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
TABLE 71 VIRIOS THERAPEUTICS, INC.: PRODUCT BENCHMARKING
TABLE 72 VIRIOS THERAPEUTICS, INC.: KEY DEVELOPMENTS
TABLE 73 ASTELLAS PHARMA: PRODUCT BENCHMARKING
TABLE 74 ASTELLAS PHARMA: KEY DEVELOPMENTS
TABLE 75 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT BENCHMARKING
TABLE 76 INTEC PHARMA S.R.O.: PRODUCT BENCHMARKING
TABLE 77 APTINYX INC.: PRODUCT BENCHMARKING
TABLE 78 APTINYX INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL FIBROMYALGIA TREATMENT MARKET SEGMENTATION
FIGURE 2 RESEARCH TIMELINES
FIGURE 3 DATA TRIANGULATION
FIGURE 4 MARKET RESEARCH FLOW
FIGURE 5 DATA SOURCES
FIGURE 6 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS, 2023-30
FIGURE 7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
FIGURE 8 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
FIGURE 9 FUTURE MARKET OPPORTUNITIES
FIGURE 10 NORTH AMERICA DOMINATED THE MARKET IN 2021
FIGURE 11 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
FIGURE 12 PORTER’S FIVE FORCES ANALYSIS FOR GLOBAL FIBROMYALGIA TREATMENT MARKET
FIGURE 13 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
FIGURE 14 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS
FIGURE 15 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
FIGURE 16 U.S. MARKET SNAPSHOT
FIGURE 17 CANADA MARKET SNAPSHOT
FIGURE 18 MEXICO MARKET SNAPSHOT
FIGURE 19 GERMANY MARKET SNAPSHOT
FIGURE 20 U.K. MARKET SNAPSHOT
FIGURE 21 FRANCE MARKET SNAPSHOT
FIGURE 22 ITALY MARKET SNAPSHOT
FIGURE 23 SPAIN MARKET SNAPSHOT
FIGURE 24 REST OF EUROPE MARKET SNAPSHOT
FIGURE 25 CHINA MARKET SNAPSHOT
FIGURE 26 INDIA MARKET SNAPSHOT
FIGURE 27 JAPAN MARKET SNAPSHOT
FIGURE 28 REST OF ASIA PACIFIC MARKET SNAPSHOT
FIGURE 29 BRAZIL MARKET SNAPSHOT
FIGURE 30 ARGENTINA MARKET SNAPSHOT
FIGURE 31 REST OF LATIN AMERICA MARKET SNAPSHOT
FIGURE 32 UAE MARKET SNAPSHOT
FIGURE 33 SAUDI ARABIA MARKET SNAPSHOT
FIGURE 34 SOUTH AFRICA MARKET SNAPSHOT
FIGURE 35 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
FIGURE 36 KEY STRATEGIC DEVELOPMENTS
FIGURE 37 ACE MATRIX
FIGURE 38 PFIZER INC.: COMPANY INSIGHT
FIGURE 1 PFIZER INC.: SEGMENT BREAKDOWN
FIGURE 2 PFIZER INC.: SWOT ANALYSIS
FIGURE 3 NOVARTIS AG: COMPANY INSIGHT
FIGURE 4 NOVARTIS AG: BREAKDOWN
FIGURE 5 NOVARTIS AG: SWOT ANALYSIS
FIGURE 6 ABBVIE: COMPANY INSIGHT
FIGURE 7 ABBVIE: SEGMENT BREAKDOWN
FIGURE 8 ABBVIE: SWOT ANALYSIS
FIGURE 9 ELI LILLY AND COMPANY: COMPANY INSIGHT
FIGURE 10 ELI LILLY AND COMPANY: BREAKDOWN
FIGURE 11 VIRIOS THERAPEUTICS, INC.: COMPANY INSIGHT
FIGURE 12 ASTELLAS PHARMA: COMPANY INSIGHT
FIGURE 13 ASTELLAS PHARMA: SEGMENT BREAKDOWN
FIGURE 14 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY INSIGHT
FIGURE 15 SUN PHARMACEUTICAL INDUSTRIES LTD.: SEGMENT BREAKDOWN
FIGURE 16 INTEC PHARMA S.R.O.: COMPANY INSIGHT
FIGURE 17 APTINYX INC.: COMPANY INSIGHT
FIGURE 18 PRISMIC PHARMACEUTICALS: COMPANY INSIGHT
FIGURE 19 PRISMIC PHARMACEUTICALS: PRODUCT BENCHMARKING
Report Research Methodology
Verified Market Research uses the latest researching tools to offer accurate data insights. Our experts deliver the best research reports that have revenue generating recommendations. Analysts carry out extensive research using both top-down and bottom up methods. This helps in exploring the market from different dimensions.
This additionally supports the market researchers in segmenting different segments of the market for analysing them individually.
We appoint data triangulation strategies to explore different areas of the market. This way, we ensure that all our clients get reliable insights associated with the market. Different elements of research methodology appointed by our experts include:
Exploratory data mining
Market is filled with data. All the data is collected in raw format that undergoes a strict filtering system to ensure that only the required data is left behind. The leftover data is properly validated and its authenticity (of source) is checked before using it further. We also collect and mix the data from our previous market research reports.
All the previous reports are stored in our large in-house data repository. Also, the experts gather reliable information from the paid databases.
For understanding the entire market landscape, we need to get details about the past and ongoing trends also. To achieve this, we collect data from different members of the market (distributors and suppliers) along with government websites.
Last piece of the ‘market research’ puzzle is done by going through the data collected from questionnaires, journals and surveys. VMR analysts also give emphasis to different industry dynamics such as market drivers, restraints and monetary trends. As a result, the final set of collected data is a combination of different forms of raw statistics. All of this data is carved into usable information by putting it through authentication procedures and by using best in-class cross-validation techniques.
Data Collection Matrix
| Perspective | Primary Research | Secondary Research |
|---|---|---|
| Supplier side |
|
|
| Demand side |
|
|
Econometrics and data visualization model
Our analysts offer market evaluations and forecasts using the industry-first simulation models. They utilize the BI-enabled dashboard to deliver real-time market statistics. With the help of embedded analytics, the clients can get details associated with brand analysis. They can also use the online reporting software to understand the different key performance indicators.
All the research models are customized to the prerequisites shared by the global clients.
The collected data includes market dynamics, technology landscape, application development and pricing trends. All of this is fed to the research model which then churns out the relevant data for market study.
Our market research experts offer both short-term (econometric models) and long-term analysis (technology market model) of the market in the same report. This way, the clients can achieve all their goals along with jumping on the emerging opportunities. Technological advancements, new product launches and money flow of the market is compared in different cases to showcase their impacts over the forecasted period.
Analysts use correlation, regression and time series analysis to deliver reliable business insights. Our experienced team of professionals diffuse the technology landscape, regulatory frameworks, economic outlook and business principles to share the details of external factors on the market under investigation.
Different demographics are analyzed individually to give appropriate details about the market. After this, all the region-wise data is joined together to serve the clients with glo-cal perspective. We ensure that all the data is accurate and all the actionable recommendations can be achieved in record time. We work with our clients in every step of the work, from exploring the market to implementing business plans. We largely focus on the following parameters for forecasting about the market under lens:
- Market drivers and restraints, along with their current and expected impact
- Raw material scenario and supply v/s price trends
- Regulatory scenario and expected developments
- Current capacity and expected capacity additions up to 2027
We assign different weights to the above parameters. This way, we are empowered to quantify their impact on the market’s momentum. Further, it helps us in delivering the evidence related to market growth rates.
Primary validation
The last step of the report making revolves around forecasting of the market. Exhaustive interviews of the industry experts and decision makers of the esteemed organizations are taken to validate the findings of our experts.
The assumptions that are made to obtain the statistics and data elements are cross-checked by interviewing managers over F2F discussions as well as over phone calls.
Different members of the market’s value chain such as suppliers, distributors, vendors and end consumers are also approached to deliver an unbiased market picture. All the interviews are conducted across the globe. There is no language barrier due to our experienced and multi-lingual team of professionals. Interviews have the capability to offer critical insights about the market. Current business scenarios and future market expectations escalate the quality of our five-star rated market research reports. Our highly trained team use the primary research with Key Industry Participants (KIPs) for validating the market forecasts:
- Established market players
- Raw data suppliers
- Network participants such as distributors
- End consumers
The aims of doing primary research are:
- Verifying the collected data in terms of accuracy and reliability.
- To understand the ongoing market trends and to foresee the future market growth patterns.
Industry Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|---|---|
|
|
